Paradigm, Therapeutics

Paradigm Therapeutics, Inc. Announces Investment by Eshelman Ventures, LLC to Support Completion of Development of SD-101 , A Topical Therapy for Treatment Across the Entire Skin Surface of All Subtypes of Epidermolysis Bullosa

Published on 08/07/2025 at 18:08 | prnewswire.co.uk

Paradigm Therapeutics, Inc. South Carolina

en | boerse | 67932746 |